Shares of Cytori Therapeutics, Inc. (NASDAQ:CYTX) are currently poised at 3.80% from the open today and are trading at $1.84. More than 10,490,412 shares have exchanged hands compared to an average trading volume of 144.20K. At the current pps, the market cap stands at $33.89M. The stock prices of Cytori Therapeutics, Inc. (NASDAQ:CYTX) are currently trading at -65.98% below its 52 week high and 36.09% above its 52 week low.
Cytori Therapeutics, Inc. (NASDAQ:CYTX) has been in the news for all the right reasons. Recently, Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced that Gregg Lapointe has joined the Company’s Board of Directors to serve as an independent director, effective March 31, 2017.
Mr. Lapointe has over 20 years of experience in the pharmaceutical and medical device industries.
Cytori Therapeutics, Inc. (NASDAQ:CYTX) is all set to announce its earnings on Mar 23/a. As per Zack’s analyst ratings, Cytori Therapeutics, Inc. (NASDAQ:CYTX) currently has an average brokerage rating of 1. On a scale of 1 to 5, a rating of 1 or 2 would indicate a buy, and a rating of 4 or 5 would signify a sell recommendation. A rating of 3 would indicate a hold on the stock. The consensus target price on (NASDAQ:CYTX) is $8.375 with a high of $10 and a low of $6.75.
Let’s take a look at the technical analysis.
The Barchart Technical Opinion rating is a 64% Buy with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.
The The Exponential Moving Average (EMA) is similar to a simple moving average (average price over a set period) but it utilizes a weighting factor that exponentially declines from the most recent data point (recent prices are weighted higher than oid prices). EMA analysis compares the short term (5 days and 13 days), intermediate term (20 days) and long term (50 days) EMA’s. The respective EMA’s will give bullish signals when trading above trailing EMA’s and below the current price and vice versa. EMA alerts include crossovers (i.e the 5 day EMA crosses above/below the 20 day EMA) and EMA convergencies (5 day EMA equivalent to 13 day EMA). The 5 day EMA 1.46 is higher than the last trade price suggesting a short term bearish pattern building up. Long term, the 50 day EMA 1.62 is also higher than the current trading price depicting a bearish trend overall..
The relative strength index (RSI) is a momentum osciallator that is able to measure the velocity and magnitude of stock price changes. Momentum is calculated as the ratio of positive price changes to negative price changes. The RSI analysis compares the current RSI against neutral(50), oversold (30) and overbought (70) conditions. Alerts will inform you when stocks recede from oversold/overbought levels or breakthrough neutral (50). The current RSI is 22.71 suggesting a bearish price action.
As such, while we believe Cytori Therapeutics, Inc. (NASDAQ:CYTX)represents a compelling growth story exposed to several secularly attractive markets, it would be interesting to see how it fairs for long-term investors.
Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company’s preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient’s own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients.